Clinical Trial Update: PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for PERMAD exploring personalized marker-driven early switch to aflibercept in metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: University of Ulm | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN